Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients

NCT02361424 is registered in ClinicalTrials.gov with Pharnext S.C.A. as lead sponsor.

NCT NCT02361424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02361424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients
Lead sponsor
Pharnext S.C.A.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2013
Completion date
June 30, 2015
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease